Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis

Background and Purpose— The purpose of this study was to conduct a meta-analysis of CVOTs (cardiovascular outcome trials) to evaluate the effect of glucagon-like peptide-1 receptor agonists therapy in reducing the risk of stroke in patients with type 2 diabetes mellitus. Methods— PubMed and other electronic sources were searched until June 20, 2019, to identify relevant studies. Hazard ratios with 95% CIs were used as a measure of the association between use of glucagon-like peptide-1 receptor agonists and risk of stroke after pooling data across trials. Results— Seven CVOTs with 56 004 participants were identified. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus was associated with 15% lower risk of nonfatal stroke ( P =0.002), 19% lower risk of fatal stroke ( P =0.150), and 16% lower risk of total stroke ( P =0.001). There was no association between reductions of hemoglobin A1c levels or body weight and risk of stroke. Conclusions— Glucagon-like peptide-1 receptor agonists reduce the risk of nonfatal stroke in patients with T2D.